Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Biomarker Research Année : 2024

Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients

David Pérez Compte
  • Fonction : Auteur
Lucas Etourneau
  • Fonction : Auteur
Anne-Marie Hesse
  • Fonction : Auteur
Alexandra Kraut
  • Fonction : Auteur
Justine Barthelon
  • Fonction : Auteur
Nathalie Sturm
  • Fonction : Auteur
Hélène Borges
  • Fonction : Auteur
Salomé Biennier
  • Fonction : Auteur
Marie Courçon
  • Fonction : Auteur
Marc de Saint Loup
  • Fonction : Auteur
Victoria Mignot
  • Fonction : Auteur
Charlotte Costentin
  • Fonction : Auteur
Yohann Couté
  • Fonction : Auteur
Christophe Bruley
  • Fonction : Auteur
Thomas Decaens
  • Fonction : Auteur
Michel Jaquinod
  • Fonction : Auteur
Jérôme Boursier
  • Fonction : Auteur
Virginie Brun
  • Fonction : Auteur

Résumé

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is estimated to affect 30% of the world’s population, and its prevalence is increasing in line with obesity. Liver fibrosis is closely related to mortality, making it the most important clinical parameter for MASLD. It is currently assessed by liver biopsy – an invasive procedure that has some limitations. There is thus an urgent need for a reliable non-invasive means to diagnose earlier MASLD stages. Methods: A discovery study was performed on 158 plasma samples from histologically-characterised MASLD patients using mass spectrometry (MS)-based quantitative proteomics. Differentially abundant proteins were selected for verification by ELISA in the same cohort. They were subsequently validated in an independent MASLD cohort ( n = 200). Results: From the 72 proteins differentially abundant between patients with early (F0-2) and advanced fibrosis (F3-4), we selected Insulin-like growth factor-binding protein complex acid labile subunit (ALS) and Galectin-3-binding protein (Gal-3BP) for further study. In our validation cohort, AUROCs with 95% CIs of 0.744 [0.673 – 0.816] and 0.735 [0.661 – 0.81] were obtained for ALS and Gal-3BP, respectively. Combining ALS and Gal-3BP improved the assessment of advanced liver fibrosis, giving an AUROC of 0.796 [0.731. 0.862]. The {ALS; Gal-3BP} model surpassed classic fibrosis panels in predicting advanced liver fibrosis. Conclusions: Further investigations with complementary cohorts will be needed to confirm the usefulness of ALS and Gal-3BP individually and in combination with other biomarkers for diagnosis of liver fibrosis. With the availability of ELISA assays, these findings could be rapidly clinically translated, providing direct benefits for patients.
Fichier principal
Vignette du fichier
s40364-024-00583-z.pdf (2.22 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04563728 , version 1 (30-04-2024)

Identifiants

Citer

David Pérez Compte, Lucas Etourneau, Anne-Marie Hesse, Alexandra Kraut, Justine Barthelon, et al.. Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients. Biomarker Research, 2024, 12 (1), pp.44. ⟨10.1186/s40364-024-00583-z⟩. ⟨hal-04563728⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More